Jacob Vella, MD
Interventional Pain Medicine · Montgomery, ALNPI 1467603670
Payments from drug & device makers
Across 700 payments — averaging $40.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$22K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$2K
- Si-bone, Inc.$839
- Boston Scientific$524
- Medtronic$384
- Stimwave Technologies Incorporated$360
- plus $3K from 29 others
What the payments were for
- Speaking & faculty fees$8,62430%
- Travel & lodging$2,71410%
- Food & beverage$17,09660%
- Education$330%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 375 | $21,525 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 165 | $2,031 |
| Si-bone, Inc. | 7 | $839 |
| Boston Scientific | 10 | $524 |
| Medtronic(2 entities) | 5 | $384 |
| Stimwave Technologies Incorporated | 4 | $360 |
| Forte Bio-pharma LLC | 21 | $359 |
| Collegium Pharmaceutical, Inc. | 19 | $332 |
| Nevro Corp. | 6 | $252 |
| Scilex Pharmaceuticals Inc. | 13 | $233 |
| AbbVie(2 entities) | 10 | $204 |
| Teva Pharmaceuticals USA, Inc. | 9 | $163 |
| Curonix LLC | 3 | $145 |
| Amgen | 8 | $143 |
| Akebia Therapeutics Inc | 1 | $124 |
| Arbor Pharmaceuticals, Inc. | 6 | $107 |
| Azurity Pharmaceuticals, Inc. | 5 | $86 |
| Vision Quest Industries Inc. | 1 | $73 |
| Redhill Biopharma Inc. | 4 | $68 |
| Pfizer | 4 | $56 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $48 |
| Biohaven Pharmaceuticals, Inc. | 3 | $46 |
| Novartis | 2 | $43 |
| Daiichi Sankyo Inc. | 2 | $41 |
| SPR Therapeutics, Inc | 2 | $40 |
| Biodelivery Sciences International, Inc. | 2 | $36 |
| Vertos Medical, Inc. | 1 | $34 |
| Stryker | 2 | $34 |
| Hologic Sales And Service, LLC | 1 | $32 |
| Saluda Medical Americas, Inc. | 1 | $26 |
| Vertex | 1 | $22 |
| Nalu Medical, Inc. | 1 | $17 |
| Neuronetics, Inc. | 1 | $14 |
| Radius Health, Inc. | 1 | $14 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PROCLAIM$13,372
- Proclaim IPG$1,206
- IFUSE IMPLANT SYSTEM$570
- Prolate$570
- Proclaim Family of SCS IPGs$454
- INTELLIS$230
- Nalocet$142
- Vafseo$124
- WAVEWRITER ALPHA$121
- Prodigy Family of SCS IPGs$120
- ARTISAN$118
- SPECTRA WAVEWRITER$106
- Senza Spinal Cord Stimulation System$104
- Proclaim DRG IPG$103
How this compares
$28,467 in reported general payments places this provider in the 90th percentile of 33 interventional pain medicine providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 4,039 | $122,879 |
| RelistorMethylnaltrexone Bromide | 39 | $91,147 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 4,758 | $83,362 |
| MovantikNaloxegol Oxalate | 114 | $47,624 |
| Pregabalin | 2,515 | $41,119 |
| Gabapentin | 3,300 | $38,396 |
| Xtampza ErOxycodone Myristate | 79 | $35,996 |
| Buprenorphine | 121 | $34,738 |
| BelbucaBuprenorphine Hcl | 38 | $33,887 |
| Lidocaine | 357 | $27,282 |
| ZtlidoLidocaine | 54 | $20,969 |
| LinzessLinaclotide | 27 | $14,347 |
| Tizanidine Hcl | 1,694 | $13,512 |
| Diclofenac Sodium | 476 | $10,971 |
| Cyclobenzaprine Hcl | 1,205 | $9,756 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCRelistor | $2,031 | $91,14739 claims |
| Collegium Pharmaceutical, Inc.Xtampza Er, Belbuca | $332 | $69,883117 claims |
| Redhill Biopharma Inc.Movantik | $68 | $47,624114 claims |
| Scilex Pharmaceuticals Inc.Ztlido | $233 | $20,96954 claims |
| AbbVieLinzess | $204 | $14,34727 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 33 interventional pain medicine providers in Alabama.
Other interventional pain medicine in Montgomery
- Bradley KatzMontgomery$12K
- David HerrickMontgomery$9K
- John MarsellaMontgomery$8K
- Roger KempMontgomery$74
- Michael KendrickBirmingham$90K
- Bradley WargoMuscle Shoals$41K
- John IronsVestavia$22K
- Richard WebbFoley$18K
- Ryan AlmeidaBirmingham$14K
- Roberto ChangHoover$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.